Artificial intelligence (AI) and psychedelic medicines are among the most high-profile evolving disruptive innovations within mental healthcare in recent years. Although AI and psychedelics may not have historically shared any common ground, there exists the potential for these subjects to combine in generating innovative mental health treatment approaches. In order to inform our perspective, we conducted a scoping review of relevant literature up to late August 2024 via PubMed intersecting AI with psychomedical use of psychedelics. Our perspective covers the potential application of AI in psychedelic medicine for: drug discovery and clinical trial optimization (including pharmacodynamics); study design; understanding psychedelic experiences; personalization of treatments; clinical screening, delivery, and follow-up (potentially delivered via chatbots/apps); application of psychological preparation, integration, and general mental health support; its role in enhancing treatment via brain modulatory devices (including virtual reality and haptic suits); and the consideration of ethical and security safeguards. Challenges include the need for sufficient data protection and security, and a range of necessary ethical protections. Future avenues of exploration could involve directly administering psychedelics (or providing algorithm-generated effects) to inorganic AI-interfaced neural networks that may exceed human brain activity (i.e., cognitive capacity) and intelligence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/nyas.15229 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COX-2 Inhibitor Prediction With KNIME: A Codeless Automated Machine Learning-Based Virtual Screening Workflow.
J Comput Chem
January 2025
Pharmaceutical Chemistry Research Laboratory 1, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, India.
Cyclooxygenase-2 (COX-2) is an enzyme that plays a crucial role in inflammation by converting arachidonic acid into prostaglandins. The overexpression of enzyme is associated with conditions such as cancer, arthritis, and Alzheimer's disease (AD), where it contributes to neuroinflammation. In silico virtual screening is pivotal in early-stage drug discovery; however, the absence of coding or machine learning expertise can impede the development of reliable computational models capable of accurately predicting inhibitor compounds based on their chemical structure.
View Article and Find Full Text PDFExploring Health Sciences Students' Perspectives on Using Generative Artificial Intelligence in Higher Education: A Qualitative Study.
Nurs Health Sci
March 2025
Faculty of Nursing, Nursing Department, Ataturk University, Erzurum, Turkey.
The widespread adoption of artificial intelligence (AI) tools in academic settings has the potential to revolutionize learning experiences, enhance educational outcomes, and streamline academic processes. The aim of this research was to explore the perceptions of Lebanese health sciences students regarding the use of generative AI in higher education. A qualitative descriptive research design informed by descriptive phenomenology was employed.
View Article and Find Full Text PDFDeep learning multi-classification of middle ear diseases using synthetic tympanic images.
Acta Otolaryngol
January 2025
Department of Otorhinolaryngology, Institute of Science Tokyo, Tokyo, Japan.
Background: Recent advances in artificial intelligence have facilitated the automatic diagnosis of middle ear diseases using endoscopic tympanic membrane imaging.
Aim: We aimed to develop an automated diagnostic system for middle ear diseases by applying deep learning techniques to tympanic membrane images obtained during routine clinical practice.
Material And Methods: To augment the training dataset, we explored the use of generative adversarial networks (GANs) to produce high-quality synthetic tympanic images that were subsequently added to the training data.
Integrating Model-Informed Drug Development With AI: A Synergistic Approach to Accelerating Pharmaceutical Innovation.
Clin Transl Sci
January 2025
Global Biometrics and Data Management, Pfizer Research and Development, New York, New York, USA.
The pharmaceutical industry constantly strives to improve drug development processes to reduce costs, increase efficiencies, and enhance therapeutic outcomes for patients. Model-Informed Drug Development (MIDD) uses mathematical models to simulate intricate processes involved in drug absorption, distribution, metabolism, and excretion, as well as pharmacokinetics and pharmacodynamics. Artificial intelligence (AI), encompassing techniques such as machine learning, deep learning, and Generative AI, offers powerful tools and algorithms to efficiently identify meaningful patterns, correlations, and drug-target interactions from big data, enabling more accurate predictions and novel hypothesis generation.
View Article and Find Full Text PDFBioinspired Smart Triboelectric Soft Pneumatic Actuator-Enabled Hand Rehabilitation Robot.
Adv Mater
January 2025
Division of Intelligent and Biomechanical Systems, State Key Laboratory of Tribology in Advanced Equipment, Department of Mechanical Engineering, Tsinghua University, Haidian, Beijing, 100084, China.
Quantitative assessment for post-stroke spasticity remains a significant challenge due to the encountered variable resistance during passive stretching, which can lead to the widely used modified Ashworth scale (MAS) for spasticity assessment depending heavily on rehabilitation physicians. To address these challenges, a high-force-output triboelectric soft pneumatic actuator (TENG-SPA) inspired by a lobster tail is developed. The bioinspired TENG-SPA can generate approximately 20 N at 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!